Rituximab in lymphocyte-predominant Hodgkin disease

Oncology

Volumn 76, Issue 1, 2008, Pages 26-29

  Azim Jr , Hatem A ^a   Pruneri, Giancarlo ^a   Cocorocchio, Emilia ^a   Cinieri, Saverio ^a,b   Raviele, Paola R ^a   Bassi, Simona ^a   Preda, Lorenzo ^a   Martinelli, Giovanni ^a   Peccatori, Fedro A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b PERRINO HOSPITAL   (Italy)

Author keywords

CD20; Lymphocyte predominant Hodgkin disease; Rituximab

Indexed keywords

RITUXIMAB;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; MONOTHERAPY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 56449105134     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000177953     Document Type: Article

References (7)

1. Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, Poppema S, Harris M, Franssila K, van Krieken J, Marafioti T, Anagnostopoulos I, Stein H: Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma project on lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1999;17:776-783.
2. Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES, Han J, van Krieken JM, Poppema S, Marafioti T, Franklin J, Sextro M, Diehl V, Stein H: European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histological and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000;96:1889-1899.
3. Nogova L, Reineke T, Brillant C, Sieniawski M, Rudiger T, Josting A, Bredenfeld H, Skripnittchenko R, Muller RP, Muller-Hermelink K, Diehl V, Engert A: Lymphocyte-predominant and classic Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008;26:434-439.
4. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B: Long-term results of RCHOP study in the treatment of the elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-4126.
5. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V: Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
6. Horning SJ, Bartlett NL, Breslin S, Advani RH, Hoppe RT, Ekstrand BC, Lucas JB: Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD). Blood (ASH Annual Meeting Abstracts) 2007;110:644.
7. Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rudiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111:109-111.